戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  memory B cells as well as the production of fully human antibodies.
2  sets the stage for using E. coli to produce fully human antibodies.
3                                            A fully human antibody, 19G9, was generated against mindin
4 b phage display library, we have generated a fully human antibody (A12) that binds to the IGF-IR with
5  effective and safe immunotherapeutic drugs, fully-human antibodies affinity-matured in a healthy hos
6                               Panitumumab, a fully human antibody against the epidermal growth factor
7  antibodies (that are rapidly convertible to fully human antibodies) and have fully functional humora
8 rated timelines necessitate the discovery of fully human antibodies as biotherapeutics using transgen
9 ng a valuable platform for the generation of fully human antibodies as therapeutics.
10 hesis clinically, we developed (89)Zr-5B1, a fully human, antibody-based radiotracer targeting tumor-
11                                     FOR46, a fully human antibody conjugated to monomethyl auristatin
12 latory approval of panitumumab (Vectibix), a fully human antibody directed against epidermal growth f
13                                      Being a fully human antibody, E7.6.3 is expected to exhibit mini
14                                         This fully human antibody has not progressed as a therapeutic
15  in which maytansinoid (DM1) was linked to a fully human antibody IgG78 through an uncleavable SMCC l
16 med by the rapid progression of 10 different fully human antibodies into human clinical trials.
17 use that produces a class of highly diverse, fully human, antibody-like agents.
18                               We generated a fully human antibody (MAA868) that binds the catalytic d
19 e the identification and characterisation of fully human antibody MEDI-579, which binds with high aff
20 st evolutionary system for the generation of fully human antibody medicines.
21 onoclonal antibodies, allowing the design of fully human antibodies of any specificity and for divers
22 immunoglobulin G1 Fc region to construct the fully human antibody scFv-FcC21, which recognized tumors
23                              Ipilimumab is a fully human antibody targeting CTLA-4 that received FDA
24                               Panitumumab, a fully human antibody targeting the epidermal growth fact
25 protein, which yielded a large collection of fully human antibodies that were characterized for bindi
26                                MEDI-573 is a fully human antibody that neutralizes both IGF-I and IGF
27                   Additionally, Fab A11 is a fully human antibody that specifically inhibits matripta
28 nomics and with methods now in place to make fully human antibodies, the potential of antibodies as v
29 ional engineering methodology for generating fully human antibody therapeutics from murine mAbs produ
30 n enables the mice to generate high affinity fully human antibodies to multiple antigens, including h
31 een used to generate numerous high-affinity, fully human antibodies to targets in multiple disease in
32 14 patients with metastatic melanoma using a fully human antibody to cytotoxic T-lymphocyte antigen-4
33                               Dupilumab is a fully human antibody to interleukin-4 receptor alpha tha
34                               Nivolumab is a fully human antibody which is routinely used at first th
35 mor necrosis factor alpha, we have generated fully human antibodies with 59, 46, and 45 substitutions